Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

被引：10
|
作者：
Pratz, Keith W.
DiNardo, Courtney D.
Selleslag, Dominik
Li, Junmin
Yamamoto, Kazuhito
Konopleva, Marina
McDonald, Andrew
Babu, Sunil
Stevens, Don A.
Kantarjian, Hagop M.
Traina, Fabiola
Venditti, Adriano
Mayer, Jiri
Montez, Melissa
Ramsingh, Giridharan
Jin, Huan
Ainsworth, William
Duan, Yinghui
Svensson, Anders Erik
Werner, Michael
Potluri, Jalaja
Jonas, Brian A.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134832
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
    Mims, Alice
    Xie, Zhuoer
    Potluri, Ravi
    Rotter, David
    Chevli, Manoj
    Prebet, Thomas
    Gaugler, Lona
    Strocchia, Maria
    Vasconcelos, Alberto
    Sieluk, Jan
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 479 - 487
  • [42] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [43] Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib plus Azacitidine
    DiNardo, Courtney D.
    Marchione, Dylan
    Heuser, Michael
    Hui, Jianan
    Gianolio, Diego
    Daigle, Scott
    Choe, Sung
    Patel, Prapti
    De Botton, Stephane
    Dohner, Hartmut
    BLOOD, 2023, 142
  • [44] Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax plus Hypomethylating Agent
    Elbeih, Azeem
    Ghosoun, Nour
    Mccullough, Kristen B.
    Johnson, Isla
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Elliott, Michelle A.
    Mangaonkar, Abhishek A.
    Matin, Aasiya
    Saliba, Antoine N.
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Mangaonkar, Abhisek
    Shah, Aasiya Mithun, V
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Arana, Cecilia Y.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2024, 144 : 2853 - 2853
  • [45] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [46] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [47] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
  • [48] Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
    Cui, Jingying
    Chen, Xuexing
    Li, Chunfang
    Yan, Qiong
    Yuan, Guolin
    HEMATOLOGY, 2024, 29 (01)
  • [49] DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS
    Zannoni, L.
    Forte, D.
    Sartor, C.
    Cristiano, G.
    Nanni, J.
    Parisi, S.
    Zingarelli, F.
    Bandini, L.
    Testoni, N.
    Ottaviani, E.
    Paolini, S.
    Papayannidis, C.
    Cavo, M.
    Rutella, S.
    Curti, A.
    HAEMATOLOGICA, 2024, 109 : 74 - 75
  • [50] Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Lu, Wenyi
    Chen, Xiangli
    Zang, Yuzhu
    Zhu, Zunmin
    Zhang, Wenhui
    Hai, Yanliang
    Chen, Yuqing
    Jiang, Li
    Xing, Yanyan
    Liu, Yuanbo
    Shi, Jie
    Gao, Zhenxing
    BLOOD, 2024, 144 : 6037 - 6037
12345